Sign In
Buy BIO
$304.83
-1.30 (-0.425%)
At Close: Jun 03, 2026
Virpax® Pharmaceuticals to Present at 2024 BIO International Convention
07:30am, Wednesday, 29'th May 2024
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax to Present at 2024 BIO International Convention.
Predictive Oncology Announces CEO Raymond Vennare to Present at the BIO International Convention 2024
07:00am, Wednesday, 29'th May 2024
Presentation to highlight Company's novel application of AI/machine learning capabilities utilizing its proprietary biobank of more than 150,000 tumor samples to guide leading biopharma partners throu
Acasti Pharma to Attend BIO International Convention 2024
04:05pm, Tuesday, 28'th May 2024
PRINCETON, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel, injectable formulation of nim
BIO-key International, Inc. Receives Notice of Non-Compliance from Nasdaq
04:30pm, Friday, 24'th May 2024
WALL, N.J., May 24, 2024 (GLOBE NEWSWIRE) -- BIO-key International, Inc. (Nasdaq: BKYI), an innovative provider of workforce and customer identity and access management (IAM) solutions featuring Ident
Bio-Rad's Management to Participate in Fireside Chat During Jefferies Global Healthcare Conference
04:15pm, Thursday, 23'rd May 2024
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Executiv
BIO-TECHNE TO PRESENT AT THE 2024 LEERINK PARTNERS HEALTHCARE CROSSROADS CONFERENCE
07:00am, Thursday, 23'rd May 2024
MINNEAPOLIS , May 23, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer will present at the 2024 Leerink Partners He
Entero Therapeutics to Present Corporate Update at 2024 BIO International Convention
07:00am, Wednesday, 22'nd May 2024
Late clinical-stage company to provide update on Phase 3 treatment for celiac disease Late clinical-stage company to provide update on Phase 3 treatment for celiac disease
MINNEAPOLIS, May 22, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Regulus Therapeutics Inc., a biopharmaceutical company focused on the discovery and development of innovative medici
Reviva to Participate in the BIO International Convention
08:00am, Tuesday, 21'st May 2024
CUPERTINO, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies t
BIO-key Expects to File Audited 2023 Results on Form 10-K and Report Q1 2024 Results and Host an Investor Call Next Week
04:55pm, Thursday, 16'th May 2024
HOLMDEL, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- BIO-key ® International, Inc. (Nasdaq: BKYI), an innovative provider of workforce and customer Identity and Access Management (IAM) solutions featuring
Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Margins Down
01:20pm, Wednesday, 08'th May 2024
Bio-Rad's (BIO) Clinical Diagnostics arm registers growth in Q1, primarily driven by an increased demand for quality control, blood typing, and diabetes products.
Bio-Rad Laboratories, Inc. (BIO) Q1 2024 Earnings Call Transcript
11:16pm, Tuesday, 07'th May 2024
Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q1 2024 Earnings Conference Call May 7, 2024 5:00 PM ET Company Participants Edward Chung - Head, Investor Relations Norman Schwartz - Chief Executive Officer An
Bio-Rad Laboratories (BIO) Q1 Earnings Surpass Estimates
06:31pm, Tuesday, 07'th May 2024
Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.29 per share, beating the Zacks Consensus Estimate of $2.04 per share. This compares to earnings of $3.34 per share a year ago.
Bio-Rad Laboratories reiterates 2024 revenue growth outlook; shares slip
06:11pm, Tuesday, 07'th May 2024
Diagnostics firm Bio Rad Laboratories reiterated its 2024 sales growth forecast on Tuesday, weighed by persistently weak spending by biotech companies and sluggish demand in China.
Bio-Rad Reports First-Quarter 2024 Financial Results
04:15pm, Tuesday, 07'th May 2024
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for t
